• Rapid Developability Assessment Of Early Phase Molecules: Parallel Screening Of Enabling Technologies And Use Of PBPK Modeling

    Scaling-up liquid formulations can present a number of challenges and headaches. This is especially true for complex solutions, suspensions and emulsions as well as biologics, sterile products, potent compounds and sensitive APIs. In this webcast, learn about potential formulation and filling issues when transitioning a liquid formulation from feasibility through commercialization.

  • Complex Liquid Formulations: Solutions For Scale-Up Challenges

    Scaling-up liquid formulations can present a number of challenges and headaches. In this webinar product development experts share insights on a variety of formulation issues including mixing, solubility, microfluidization, viscosity, filtration and special API handling, with discussed solutions based on Catalent’s expertise in complex formulation.

  • Sources, Effects, And The Importance Of Elemental Impurities For Finished Drug Products

    Elemental impurities can arise from a variety of sources, such as active pharmaceutical ingredients (API), excipients, manufacturing equipment, and primary container closure systems.  ICH Q3D recommends that manufacturers conduct a product risk assessment by identifying and assessing known and potential sources of elemental impurities.  This webinar reviews the impact of the most recent regulatory changes related to elemental impurities testing, guidance on the best routes to compliance, and an overview of the elemental impurities risk assessment process.

  • Coating: Curing Your Complex Oral Solid Dose Challenges

    Pfizer CentreOne’s oral solid dose experts discuss how advances in the mathematics and engineering involved in understanding the process can tackle these challenges and ensure functional coating and drug layering continue to be a viable solution for the next generation of OSD drug products. Discover how coatings expertise could transform your OSD drug.